Mental illnesses are a global health challenge, and effective medicines are needed to treat
these conditions. Psychotropic drugs are commonly prescribed to manage mental disorders …

Understanding the pathophysiology of Alzheimer's disease (AD) is essential to improve the
efficacy of treatments and, consequently, patients' lives. Unfortunately, traditional therapeutic …

KW-6356 is a novel adenosine A2A (A2A) receptor antagonist/inverse agonist, and its
efficacy as monotherapy in Parkinson's disease (PD) patients has been reported …

KW-6356 is a novel adenosine A 2A receptor antagonist/inverse agonist that not only blocks
binding of adenosine to adenosine A 2A receptor but also inhibits the constitutive activity of …

The adenosine A 2A receptor antagonist/inverse agonist, KW-6356 has been shown to be
effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to …

Based on a screening of a chemical library of A2A adenosine receptor (AR) antagonists, a
series of di-and tri-substituted adenine derivatives were synthesized and tested for their …

G protein-coupled receptors (GPCRs) are the target of hundreds of approved drugs.
Although these drugs were designed to target individual receptors, it is becoming …

Screening of compounds comprising 8-substituted guanine revealed that 8-aminoguanosine
and 8-aminoguanine cause diuresis/natriuresis/glucosuria, yet decrease potassium …

Many studies have reported metabolomic analysis of different bio-specimens from
Parkinson's disease (PD) patients. However, inconsistencies in reported metabolite …

Heteromer formation is unknown for the olfactory family of G protein-coupled receptors
(GPCRs). We here identified, in a heterologous system, heteromers formed by the …